Evidence map›Paper›PMID 35552754›Full record

ReviewThe oncologist2022

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

Ralph Boccia, John Glaspy, Jeffrey Crawford, Matti Aapro

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 5 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 5 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Pretreatment neutrophil-to-lymphocyte ratio (NLR) as a potential risk marker for febrile neutropenia (FN) in breast and ovarian cancer during first-cycle chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Ralph BocciaCenter for Cancer and Blood Disorders, Bethesda, MD, USA.
John GlaspyUCLA School of Medicine, Los Angeles, CA, USA.
Jeffrey CrawfordDuke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
Matti AaproCancer Centre, Clinique de Genolier, Genolier, Switzerland.
Center for Cancer and Blood Disorders · USClinique de Genolier · CHDuke University · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutropenia and febrile neutropenia (FN) are common complications of myelosuppressive chemotherapy. This review provides an up-to-date assessment of the patient and cost burden of chemotherapy-induced neutropenia/FN in the US, and summarizes recommendations for FN prophylaxis, including the interim guidance that was recommended during the coronavirus disease 2019 (COVID-19) pandemic. This review indicates that neutropenia/FN place a significant burden on patients in terms of hospitalizations and mortality. Most patients with neutropenia/FN presenting to the emergency department will be hospitalized, with an average length of stay of 6, 8, and 10 days for elderly, pediatric, and adult patients, respectively. Reported in-hospital mortality rates for neutropenia/FN range from 0.4% to 3.0% for pediatric patients with cancer, 2.6% to 7.0% for adults with solid tumors, and 7.4% for adults with hematologic malignancies. Neutropenia/FN also place a significant cost burden on US healthcare systems, with average costs per neutropenia/FN hospitalization estimated to be up to $40 000 for adult patients and $65 000 for pediatric patients. Evidence-based guidelines recommend prophylactic granulocyte colony-stimulating factors (G-CSFs), which have been shown to reduce FN incidence while improving chemotherapy dose delivery. Availability of biosimilars may improve costs of care. Efforts to decrease hospitalizations by optimizing outpatient care could reduce the burden of neutropenia/FN; this was particularly pertinent during the COVID-19 pandemic since avoidance of hospitalization was needed to reduce exposure to the virus, and resulted in the adaptation of recommendations to prevent FN, which expanded the indications for G-CSF and/or lowered the threshold of use to >10% risk of FN.

Indexed as

Antineoplastic AgentsBiosimilar PharmaceuticalsChemotherapy-Induced Febrile NeutropeniaCOVID-19 Drug TreatmentNeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChildGranulocyte Colony-Stimulating FactorHumansPandemicsAntineoplastic AgentsBiosimilar PharmaceuticalsGranulocyte Colony-Stimulating Factorcosts and cost analysisfebrile neutropeniahospitalizationmortalityUS

Identifiers

PMID35552754
PMCPMC9355811
OpenAlexW4226150097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.